MedTrace Logo

A Phase 1 Study of GZC8072 Tablets Following a Single Dose in Healthy Study Participants and Multiple Doses in Obese/Overweight Study Participants

NCT07784699 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 112

Last updated 2026-08-25

No results posted yet for this study

Summary

This trial is conducted in China. This study plans to include 2 parts, i.e., a single-dose study and a multiple-dose study:

The single-dose study will be conducted in healthy adult participants to evaluate the safety, tolerability, and pharmacokinetic profile of single doses of GZC8072 Tablets; The multiple-dose study will be conducted in obese or overweight study participants to evaluate the safety, tolerability, pharmacokinetic and pharmacodynamic profiles of multiple doses of GZC8072 Tablets.

Conditions

  • Healthy Subjects;Overweight or Obesity

Interventions

DRUG

GZC8072 Tablets

Oral drug

DRUG

Placebo

Oral drug

Sponsors & Collaborators

  • Gan & Lee Pharmaceuticals.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
OTHER
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-09-04
Primary Completion
2027-08-18
Completion
2027-08-18

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07784699 on ClinicalTrials.gov